A pivotal Phase 3 study evaluating ubrogepant for the treatment of migraine attacks during the prodrome was published on 2023-01-01. The trial investigated the acute treatment of migraine during its prodromal phase in adult participants.
Background
Ubrogepant is an oral medication that has been investigated for the acute treatment of migraine. This particular Phase 3 study focused on its use during the prodrome, the earliest phase of a migraine attack, which can include a variety of non-painful symptoms that precede the headache phase.
Trial design
The published study was a Phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial. It aimed to evaluate oral ubrogepant in the acute treatment of migraine during the prodrome in adult participants, as detailed in the study summary 'UBR Prodrome — Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants'.
What this means
The publication of this pivotal Phase 3 trial for ubrogepant in the acute treatment of migraine during the prodrome indicates a significant step in exploring treatment options for migraine at its earliest stages. While the provided data does not include specific efficacy or safety outcomes, the nature of a pivotal publication in a respected journal like The Lancet suggests that the trial yielded results considered important for the scientific and clinical community. This could potentially influence future approaches to managing migraine by intervening before the onset of headache pain.
Source
The information regarding this trial publication was sourced from PubMed, an archive of biomedical and life sciences journal literature. The article, titled "Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in t", was published on 2023-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.